In metastatic colorectal cancer, the optimization of upfront treatment and the continuum of care based on patients' exposure to multiple treatment lines have reached a plateau of efficacy. Therefore, a paradigm shift is ongoing towards precision medicine and personalized treatments based on the specific molecular features of the disease. In this perspective, the improved knowledge of disease biology coming from the lab has prompted a rapid translation from bench to bedside of newer targeted strategies. Here, we focus on the most promising biomarkers already included or close to adoption in daily clinical practice. In particular, evidence about the potential roles of BRAF mutation, HER2 amplification, MGMT methylation, microsatellite instability, and ALK, ROS and NTRK1-3 rearrangements as positive predictors of benefit from biological agents is reviewed and discussed.

How the lab is changing our view of colorectal cancer / C. Cremolini, F. Pietrantonio. - In: TUMORI. - ISSN 0300-8916. - 102:6(2016 Dec), pp. 541-547. [10.5301/tj.5000551]

How the lab is changing our view of colorectal cancer

F. Pietrantonio
Ultimo
2016

Abstract

In metastatic colorectal cancer, the optimization of upfront treatment and the continuum of care based on patients' exposure to multiple treatment lines have reached a plateau of efficacy. Therefore, a paradigm shift is ongoing towards precision medicine and personalized treatments based on the specific molecular features of the disease. In this perspective, the improved knowledge of disease biology coming from the lab has prompted a rapid translation from bench to bedside of newer targeted strategies. Here, we focus on the most promising biomarkers already included or close to adoption in daily clinical practice. In particular, evidence about the potential roles of BRAF mutation, HER2 amplification, MGMT methylation, microsatellite instability, and ALK, ROS and NTRK1-3 rearrangements as positive predictors of benefit from biological agents is reviewed and discussed.
biomarkers; colorectal cancer; precision medicine; colorectal neoplasms; dna methylation; DNA modification methylases; DNA repair enzymes; gene expression regulation, neoplastic; humans; immunotherapy; microsatellite instability; molecular diagnostic techniques; mutation; oncogene proteins, fusion; precision medicine; promoter regions, genetic; proto-oncogene proteins b-raf; receptor, ERBB-2; tumor suppressor proteins; RAS proteins; biomarkers, tumor; medicine (all); oncology; cancer research
Settore MED/06 - Oncologia Medica
dic-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
N°70 How the lab is changing our view of colorectal cancer.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 679.02 kB
Formato Adobe PDF
679.02 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/563966
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact